Received Jun 5, 2026
Reports are unverified and do not show that a vaccine caused an event. Full disclaimer
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEP | HEP B (HEPLISAV-B) | DYNAVAX TECHNOLOGIES CORPORATION | 1 | 947353 | — |
A Patient Received A 1st Dose 4 Months Ago And Needs The Second Dose; Initial report received on 22-May-2026. A pharmacist reported that a 38-year-old female (race and ethnicity not provided) received the first dose of HEPLISAV-B (hepatitis B vaccine) for hepatitis B immunization and had not received the second dose yet. No medical history or concomitant medications were reported. In Jan-2026, the patient received dose 1 of a hepatitis B vaccine [HEPLISAV-B (Lot #947353, expiration date, NDC #, route and site not reported)]. At the time of reporting, approximately four months after having been vaccinated with HEPLISAV-B, the patient has not had their second dose yet. No adverse events were reported. No additional information was reported. Company Comment: The company assessed the event as non-serious.; Sender's Comments: The company assessed the event as non-serious.